Related Experiment Video
Updated: Aug 17, 2026
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design
Anastasios Dimou1, Vassiliki Papadimitrakopoulou2
1Department of Medicine, Albert Einstein Medical Center, 5501 Old York Street, Philadelphia, PA 19141, USA. dimouana@einstein.edu.
Abstract:
The approval of EGFR and ALK directed tyrosine kinase inhibitors materialized the concept of tailoring therapy on the basis of specific biomarkers for treating patients with NSCLC. Research for other biologics, although demonstrating clinical benefit, has been less successful so far for producing biomarkers that predict response. Blocking angiogenesis is the prototype for the agents that belong in the latter group that target specific molecules, yet they are currently approved for relatively unselected groups of patients. In order to meet the goal of personalizing care in the various settings of NSCLC, a wealth of biologics and compounds are currently being tested in clinical trials in different phases of clinical development. In a subset of the relevant studies, a biomarker perspective is appreciated. This review summarizes the clinical rationale of the major ongoing phase II and III NSCLC studies that employ targeting specific molecules with novel agents, as well as innovative strategies, and includes a comparative discussion of the different designs.
Insights
Biomarker-driven therapies, like those targeting EGFR and ALK, are revolutionizing non-small cell lung cancer (NSCLC) treatment. Ongoing research explores novel agents and strategies to personalize care for more effective NSCLC patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Trials
Background:
- Personalized medicine in non-small cell lung cancer (NSCLC) has advanced with biomarker-directed therapies targeting EGFR and ALK.
- While some biologics show clinical benefit, identifying predictive biomarkers for response remains a challenge for agents like anti-angiogenesis drugs.
Purpose of the Study:
- To review the clinical rationale and design of ongoing Phase II and III clinical trials for novel molecularly targeted agents in NSCLC.
- To discuss innovative treatment strategies and biomarker perspectives in NSCLC drug development.
Main Methods:
- Systematic review of major ongoing Phase II and III clinical studies in NSCLC.
- Analysis of studies employing novel targeted agents and innovative treatment strategies.
- Comparative discussion of study designs with a focus on biomarker integration.
Main Results:
- The landscape of NSCLC treatment is evolving with numerous novel agents and compounds in clinical development.
- A subset of these studies incorporates biomarker strategies to refine patient selection and predict treatment response.
- Ongoing trials explore targeted therapies beyond EGFR and ALK, including those targeting angiogenesis.
Conclusions:
- Personalizing NSCLC care requires continued investigation into novel agents and predictive biomarkers.
- Understanding the design and rationale of ongoing clinical trials is crucial for advancing targeted therapy in NSCLC.
- Future NSCLC treatment paradigms will likely involve a combination of targeted agents, innovative strategies, and robust biomarker approaches.
More Related Videos
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview